Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$5.04 -14.0%	$5.51	$2.43 ▼ $46.68	$15.25M	1.15	643,263 shs	295,670 shs
IKT Inhibikase Therapeutics	$1.71	$1.79	$1.12 ▼ $4.20	$127.13M	0.9	195,163 shs	81,201 shs
PRME Prime Medicine	$3.64 -4.5%	$3.28	$1.11 ▼ $5.17	$489.85M	2.39	2.51 million shs	2.37 million shs
TALS Talaris Therapeutics	$22.39 +0.8%	$18.84	$0.89 ▼ $27.95	$957.49M	2.18	386,531 shs	112,736 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	-13.99%	-12.50%	-26.57%	+2.44%	-73.42%
IKT Inhibikase Therapeutics	0.00%	+10.32%	-5.00%	-14.93%	+31.54%
PRME Prime Medicine	-4.46%	-1.09%	-15.15%	+128.93%	-11.44%
TALS Talaris Therapeutics	+3.45%	+1.28%	+17.19%	+43.17%	+54.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	0.7747 of 5 stars	0.0	4.0	0.0	0.0	2.5	0.0	0.6
IKT Inhibikase Therapeutics	1.7512 of 5 stars	3.3	2.0	0.0	0.0	1.1	0.0	1.3
PRME Prime Medicine	3.6896 of 5 stars	4.4	1.0	0.0	0.0	2.3	5.0	0.6
TALS Talaris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	280.12% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	144.96% Upside
TALS Talaris Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TALS, PRME, CLDI, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PRME Prime Medicine	$4.96M	98.74	N/A	N/A	$1.37 per share	2.66
TALS Talaris Therapeutics	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
TALS Talaris Therapeutics	-$73.89M	-$1.79	N/A	∞	N/A	N/A	-39.93%	-37.37%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	39.73%	N/A	N/A	N/A
TALS Talaris Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PRME Prime Medicine	N/A	6.50	6.50
TALS Talaris Therapeutics	N/A	15.41	15.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
IKT Inhibikase Therapeutics	3.81%
PRME Prime Medicine	70.37%
TALS Talaris Therapeutics	67.61%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
IKT Inhibikase Therapeutics	7.30%
PRME Prime Medicine	22.74%
TALS Talaris Therapeutics	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable
TALS Talaris Therapeutics	84	42.76 million	35.71 million	Not Optionable

TALS, PRME, CLDI, and IKT Headlines

Recent News About These Companies

Tourmaline Bio, Inc. (TRML)

August 21, 2024 | finance.yahoo.com

Coin Tales Free Spins – Updated Every Day!

July 30, 2024 | talkandroid.comT

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

April 29, 2024 | finanznachrichten.de

Longitude Venture Partners III, L.P.'s Net Worth

February 25, 2024 | benzinga.com

Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15

November 1, 2023 | msn.com

Talaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complex

October 20, 2023 | dhakatribune.comD

Talaris Therapeutics goes ex-dividend tomorrow

October 19, 2023 | msn.com

Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 18, 2023 | finanznachrichten.de

Talaris shareholders approve merger, 1-for-10 reverse stock split

October 17, 2023 | msn.com

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 17, 2023 | finance.yahoo.com

Talaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling Alert

October 16, 2023 | knoxdaily.comK

Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger

October 6, 2023 | marketwatch.com

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

October 6, 2023 | finance.yahoo.com

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

October 4, 2023 | finance.yahoo.com

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

September 12, 2023 | finance.yahoo.com

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,

August 23, 2023 | bakersfield.comB

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT

August 15, 2023 | markets.businessinsider.com

ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business

August 14, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHL

July 29, 2023 | bakersfield.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TALS, PRME, CLDI, and IKT Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$5.04 -0.82 (-13.99%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$5.30 +0.26 (+5.24%)

As of 08/14/2025 07:56 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Inhibikase Therapeutics NYSE:IKT

$1.71 0.00 (0.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.01 (+0.58%)

As of 08/14/2025 04:20 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Prime Medicine NYSE:PRME

$3.64 -0.17 (-4.46%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.01 (+0.41%)

As of 08/14/2025 07:58 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Talaris Therapeutics NASDAQ:TALS

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time